| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | TREATMENT OF AMD USING AAV SFLT-1 | EP13791695 | 2013-05-07 | EP2849802A4 | 2016-01-20 | CONSTABLE IAN J; RAKOCZY P ELIZABETH; LAI CHOOI-MAY; CHALBERG THOMAS W JR |
| 22 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EP11839800 | 2011-11-08 | EP2637502A4 | 2014-07-23 | LEE KWANGHO; NIU DEQIANG; BAEVSKY MATTHEW FRANK |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 23 | PREECLAMPTIC PLACENTAL MESENCHYMAL STEM CELL CONDITIONED MEDIUM FOR USE IN THE TREATMENT OF A TUMOUR | EP13792477.5 | 2013-10-02 | EP2903624A1 | 2015-08-12 | ROLFO, Alessandro; TODROS, Tullia |
| It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells from a preeclamptic placenta. The conditioned medium object of the invention includes at least IP-10 and TARC proteins and it is used for the therapeutic treatment of a tumor, preferably an epithelial tumor. | ||||||
| 24 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EP11839800.7 | 2011-11-08 | EP2637502A1 | 2013-09-18 | LEE, Kwangho; NIU, Deqiang; BAEVSKY, Matthew, Frank |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 25 | HETEROARYL COMPOUNDS AND USES THEREOF | EP08839939 | 2008-10-17 | EP2214486A4 | 2011-03-09 | TESTER RICHLAND W; SINGH JUSWINDER; GHOSH SHOMIR; KLUGE ARTHUR F; PETTER RUSSELL C |
| 26 | HETEROARYL COMPOUNDS AND USES THEREOF | EP08839939.9 | 2008-10-17 | EP2214486A1 | 2010-08-11 | TESTER, Richland, W.; SINGH, Juswinder; GHOSH, Shomir; KLUGE, Arthur, F.; PETTER, Russell, C. |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 27 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EP11839800.7 | 2011-11-08 | EP2637502B1 | 2018-01-10 | LEE, Kwangho; NIU, Deqiang; BAEVSKY, Matthew, Frank |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 28 | A NOVEL ISOFORM OF ANAPLASTIC LYMPHOMA KINASE AND ITS USES | EP15777435 | 2015-04-10 | EP3129477A4 | 2017-11-01 | CHI PING; WIESNER THOMAS; CHEN YU |
| 29 | A NOVEL ISOFORM OF ANAPLASTIC LYMPHOMA KINASE AND ITS USES | EP15777435.7 | 2015-04-10 | EP3129477A2 | 2017-02-15 | CHI, Ping; WIESNER, Thomas; CHEN, Yu |
| The present invention relates to a Truncated isoform of Anaplastic Lymphoma Kinase ("TALK"). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing. | ||||||
| 30 | AAV SFLT−1を用いたAMDの処置 | JP2017209139 | 2017-10-30 | JP2018015008A | 2018-02-01 | イアン ジェイ. コンスタブル; エリザベス ピー. ラコジー; チョーイ−メイ ライ; トーマス ダブリュー. チャルバーグ ジュニア |
| 【課題】薬学的有効量の、可溶性Fms関連チロシンキナーゼ1(sFlt−1)タンパク質をコードする核酸を含むベクターを含む医薬組成物を、ヒト対象へと網膜下投与することにより、ヒト対象において、AMDなどの眼の血管新生を防止または処置するための組成物および方法を提供すること。 【解決手段】 ヒト対象における眼の血管新生の処置または予防における使用のための、VEGF阻害剤をコードする配列を含む核酸であって、前記使用が、それを必要とするヒト対象における1または複数の網膜下部位へと、前記ヒト対象に有効量の医薬組成物を直接投与するステップを含み、前記医薬組成物が前記核酸を含む、核酸が提供される。 【選択図】なし |
||||||
| 31 | 変異体選択的EGFR阻害剤およびその使用 | JP2013538820 | 2011-11-08 | JP5957003B2 | 2016-07-27 | リー, クワンホー; ニュー, デチャン; バエブスキー, マシュー フランク |
| 32 | Heteroaryl compounds and their use | JP2010529960 | 2008-10-17 | JP5600063B2 | 2014-10-01 | ジャスウィンダー シン，; ショミール ゴーシュ，; アーサー エフ． クルーグ，; ラッセル シー． ペッター，; リッチランド ダブリュー． テスター， |
| 33 | Heteroaryl compound and use thereof | JP2014112633 | 2014-05-30 | JP2014156489A | 2014-08-28 | SINGH JUSWINDER; GHOSH SHOMIR; KLUGE ARTHUR F; RUSSELL C PETTER; RICHLAND W TESTER |
| PROBLEM TO BE SOLVED: To provide a heteroaryl compound and use thereof.SOLUTION: A compound of the present invention and a pharmaceutically acceptable composition thereof are useful for treating a variety of diseases, disorders or conditions related to abnormal cellular response inducing protein kinase-mediated events. Such diseases, disorders, or conditions include those described in the present specification. The compound provided by the present invention is also useful for the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of a new kinase inhibitor. | ||||||
| 34 | Heteroaryl compounds and their use | JP2010529960 | 2008-10-17 | JP2011500685A | 2011-01-06 | アーサー エフ． クルーグ，; ショミール ゴーシュ，; ジャスウィンダー シン，; リッチランド ダブリュー． テスター，; ラッセル シー． ペッター， |
| 本発明の化合物、およびその医薬的に許容される組成物は、タンパク質キナーゼが媒介する事象を誘発する異常な細胞応答に関連する種々の疾患、障害または状態を治療するのに有用である。 このような疾患、障害または状態は、本明細書に記載されているものを含む。 本発明で提供される化合物は、生体現象および病理学的な現象におけるキナーゼの研究、このようなキナーゼが媒介する細胞内シグナル伝達経路の研究、新規キナーゼ阻害剤の競争的な評価でも有用である。 | ||||||
| 35 | TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS | US15961654 | 2018-04-24 | US20180311319A1 | 2018-11-01 | Ian J. CONSTABLE; P. Elizabeth RAKOCZY; Chooi-May LAI; Thomas W. CHALBERG |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 36 | Treatment of ocular neovascularization using anti-VEGF proteins | US15851650 | 2017-12-21 | US10004788B2 | 2018-06-26 | Ian J. Constable; P. Elizabeth Rakoczy; Chooi-May Lai; Thomas W. Chalberg, Jr. |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 37 | TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS | US15851650 | 2017-12-21 | US20180125948A1 | 2018-05-10 | Ian J. CONSTABLE; P. Elizabeth RAKOCZY; Chooi-May LAI; Thomas W. CHALBERG, Jr. |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 38 | Treatment of ocular neovascularization using anti-VEGF proteins | US14281749 | 2014-05-19 | US09943573B2 | 2018-04-17 | Ian J. Constable; P. Elizabeth Rakoczy; Chooi-May Lai; Thomas W. Chalberg, Jr. |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 39 | ANTIBODY-FYNOMER CONJUGATES | US15126551 | 2015-03-16 | US20170081412A1 | 2017-03-23 | Roland NEWMAN; Steve GRANGER; Michael LYMAN; Dragan GRABULOVSKI; Richard WOODS; Michela SILACCI; Wenjuan ZHA; Isabella ATTINGER-TOLLER |
| Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities. | ||||||
| 40 | INDOLE-LIKE TRK RECEPTOR ANTAGONISTS | US15249390 | 2016-08-27 | US20170057948A1 | 2017-03-02 | Tonis Timmusk; Margus Lopp; Eero Vasar; Allen Kaasik; Mati Karelson |
| A tropomyosin receptor kinase (Trk) antagonist having a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is CH3, R2 is OCH3, R3 is SO2N(CH3)2, and R4 is H; or R1 is CH3, R2 is OH, R3 is SO2N(CH3)2, and R4 is H. | ||||||
QQ群二维码
意见反馈
意见反馈